Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy targets returning prostate cancer with precision radiation

NCT ID NCT06105918

First seen Dec 15, 2025 · Last updated May 20, 2026 · Updated 24 times

Summary

This early-stage trial tests a two-step treatment for men whose prostate cancer has returned after prostate removal surgery. First, doctors use a special scan to find exactly where the cancer is, then deliver targeted radiation. After that, patients receive a radioactive drug that seeks out and destroys remaining cancer cells. The main goal is to check if this combination is safe and to find the best dose. Only 6 men with pelvic-only recurrence are being enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.